These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36652274)

  • 81. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Wils P; Seksik P; Stefanescu C; Nancey S; Allez M; Pineton de Chambrun G; Altwegg R; Gilletta C; Vuitton L; Viennot S; Serrero M; Fumery M; Savoye G; Collins M; Goutorbe F; Brixi H; Bouguen G; Tavernier N; Boualit M; Amiot A; Abitbol V; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):460-470. PubMed ID: 33345331
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684685
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
    Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
    Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
    World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Bots SJ; Parker CE; Brandse JF; Löwenberg M; Feagan BG; Sandborn WJ; Jairath V; D'Haens G; Vande Casteele N
    BioDrugs; 2021 Nov; 35(6):715-733. PubMed ID: 34797516
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Order of Live and Inactivated Vaccines and Risk of Non-vaccine-targeted Infections in US Children 11-23 Months of Age.
    Newcomer SR; Daley MF; Narwaney KJ; Xu S; DeStefano F; Groom HC; Jackson ML; Lewin BJ; McLean HQ; Nordin JD; Zerbo O; Glanz JM
    Pediatr Infect Dis J; 2020 Mar; 39(3):247-253. PubMed ID: 32032310
    [TBL] [Abstract][Full Text] [Related]  

  • 87. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
    Chaparro M; Gisbert JP
    Expert Opin Drug Saf; 2014 Dec; 13(12):1749-62. PubMed ID: 25244582
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Discontinuation syndrome in newborns whose mothers took antidepressants while pregnant or breastfeeding.
    Hale TW; Kendall-Tackett K; Cong Z; Votta R; McCurdy F
    Breastfeed Med; 2010 Dec; 5(6):283-8. PubMed ID: 20807106
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 90. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dilemmas With Rotavirus Vaccine: The Neonate and Immunocompromised.
    Chiu M; Bao C; Sadarangani M
    Pediatr Infect Dis J; 2019 Jun; 38(6S Suppl 1):S43-S46. PubMed ID: 31205244
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Safety and Feasibility of Infliximab Therapy in Children With Kawasaki Disease Who Received Live Vaccinations.
    Ohnishi Y; Okada S; Kawakami-Miyake A; Furuta T; Fukano R; Yasudo H; Shimokawa M; Hasegawa S
    Pediatr Infect Dis J; 2022 Sep; 41(9):e388-e392. PubMed ID: 35895884
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU.
    Chaparro M; Donday MG; Abad-Santos F; Martín de Carpi FJ; Maciá-Martínez MÁ; Montero D; Acosta D; Brenes Y; Gisbert JP
    Therap Adv Gastroenterol; 2021; 14():17562848211018097. PubMed ID: 34158835
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Vaccination therapy for inflammatory bowel disease.
    Liu Y; Liao F
    Hum Vaccin Immunother; 2023 Aug; 19(2):2259418. PubMed ID: 37771317
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safety of Live-Attenuated Vaccines in Children Exposed to Biologic Response Modifiers in Utero.
    Zerbo O; Modaressi S; Goddard K; Lewis E; Getahun D; Palmsten KK; Fuller CC; Crane B; Donahue JG; Daley MF; Jackson LA; Wodi AP; McNeil MM; Klein NP
    Pediatrics; 2022 Jul; 150(1):. PubMed ID: 35773517
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The pre- and post-authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation.
    Ghalandari N; Dolhain RJEM; Hazes JMW; Siezen CLE; van der Laan JW; Crijns HJMJ; van Puijenbroek EP; van der Woude CJ
    Br J Clin Pharmacol; 2020 Mar; 86(3):580-590. PubMed ID: 31633830
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors-Literature Review and Statement of Experts from Polish Dermatological Society.
    Narbutt J; Żuber Z; Lesiak A; Bień N; Szepietowski JC
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250895
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Live attenuated vaccines in patients receiving immunosuppressive agents.
    Kamei K
    Pediatr Nephrol; 2023 Dec; 38(12):3889-3900. PubMed ID: 37076756
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A Benefit-Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini-Review.
    Bozzi LM; Jacobson MH; Yost E; Sheahan A; Cafone J; Komatsu Y; Schwartz L; Levitan B; Nelson RM
    Clin Pharmacol Ther; 2024 Jun; 115(6):1251-1257. PubMed ID: 38506485
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.